Allena Pharmaceuticals, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ALNA research report →
Price Chart
About the company
Allena Pharmaceuticals, Inc. is a biopharmaceutical company focused on the research, development, and market introduction of orally administered enzyme therapies. Operating within the United States, the firm is dedicated to addressing debilitating metabolic and renal conditions, particularly those that are rare and severe.
- CEO
- Louis Brenner
- IPO
- 2017
- Employees
- 12
- HQ
- Newton, MA, US
Get TickerSpark's AI analysis on ALNA
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $0
- P/E
- -0.07
- PEG
- -0.00
- P/S
- 0.00
- P/B
- 0.13
- EV/EBITDA
- 0.92
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -160.99%
- ROIC
- -166.72%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+0.0%
- Op Income
- $-32,335,000
- Net Income
- $-33,355,000-1.6%
- EPS
- $-1.03-2.0%
- OCF Growth
- -62.2%
- FCF Growth
- -60.9%
- Beta
- 1.15
- RSI (14)
- 31
No earnings-call transcripts are available for ALNA yet.
of shares held by institutions
23 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Level Four Financial, LLC | 40.00K | ▲ 20.00K |
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Feb 1, 22 | Katz Richard D | other | 255,000 |
| Feb 1, 22 | BRENNER LOUIS MD | other | 655,000 |
| Nov 15, 21 | BRENNER LOUIS MD | other | 125,582 |
| Nov 15, 21 | BRENNER LOUIS MD | sell | 40,328 |
| Nov 15, 21 | BRENNER LOUIS MD | other | 125,582 |
| Jun 3, 21 | Margolin Alexey L | other | 37,000 |
| Jun 3, 21 | Alexander Robert | other | 37,000 |
| Jun 3, 21 | Diaz Allene M. | other | 37,000 |
| Jun 3, 21 | SANTINI GINO | other | 37,000 |
| Jun 3, 21 | Miller Ann Calby | other | 37,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our ALNA coverage
Recent articles, reports, and earnings notes.
No research on ALNA yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ALNA report →Hot Penny Stocks to Watch Before Market Open on July 29th
pennystocks.com · Jul 29
What to Know About Buying Penny Stocks on July 7th
pennystocks.com · Jul 7
Why Shares Of Allena Pharmaceuticals Are Skyrocketing Today
benzinga.com · Jun 29
ALNA Stock Alert: What to Know as Allena Pharmaceuticals Soars 200%
investorplace.com · Jun 29
What to Know About Buying Penny Stocks on June 29th
pennystocks.com · Jun 29
What to Know About Buying Penny Stocks on June 9th
pennystocks.com · Jun 9
Trending Penny Stocks to Watch in Early June 2022
pennystocks.com · Jun 3
Best Penny Stocks to Buy in May? 3 to Watch Right Now
pennystocks.com · May 12
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.